King Buys Aventis’ Synercid, Tilade, Intal; Will Add 85 Reps To Sales Force

A potential Synercid indication in methicillin-resistant Staphylococcus aureus is one milestone trigger in King's agreement to purchase rights to the antibiotic and two asthma drugs from Aventis